Dmitry Balyasny’s Achilles Therapeutics ACHL Stock Holding History

Dmitry Balyasny’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,059	Closed	-$39K	–	3322
2022 Q3	$39K	Buy	+17,059	New	+$48.3K	﹤0.01%	2500

Other funds holding ACHL

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Dmitry Balyasny's ACHL Position: Q4 2022 in Review

Dmitry Balyasny sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 17,059 shares — an estimated $39K sold.

Dmitry Balyasny first reported a position in ACHL in Q3 2022 and held it in 1 quarter. The position peaked at $39K in Q3 2022. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

Dmitry Balyasny reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
Dmitry Balyasny sold 17,059 Achilles Therapeutics shares in Q4 2022, an estimated $39K.
Dmitry Balyasny first reported a position in Achilles Therapeutics in Q3 2022 and held it in 1 quarter.
Dmitry Balyasny's Achilles Therapeutics position peaked at $39K in Q3 2022.
23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.